News items Genetic patch inhibits blindness in patients with Usher syndrome
14 April 2021

This week (March 24th) Leiden-based biotech company ProQR Therapeutics presented the positive results of the Stellar trial, a clinical phase I/II study testing the safety and efficacy of the molecule QR-421a in 14 patients. The promising result was achieved with an agent that in its earliest phase was developed by researchers at Radboudumc.

"QR-421a is a genetic patch that allows a specific part of the USH2A gene to be covered," says Dr. Erwin van Wijk, in response to the news. "Some patients with Usher syndrome have a mistake, a mutation in that part of the gene. These hereditary errors cause people to eventually lose both their sight and their hearing. By covering the mistake with this patch, you should be able to prevent these problems. Regular, but somewhat smaller proteins will then be produced again. The expectation is that these proteins will function well enough to inhibit the deterioration of vision."

From licence to Leiden

The treatment method (exon skipping) from which ProQR's QR-421a molecule originated was developed years ago, within Van Wijk's research group. Van Wijk is part of the Hearing & Genes group that is part of the Department of ENT at Radboudumc. The specific method that was developed and patented here was licensed to ProQR. They then further developed it, in collaboration with Radboudumc, into the product that has now been tested.

Further applications

In a press release, the company has now shared that the molecule was well tolerated at all doses tested, no serious side effects were seen, and vision improved somewhat in everyone. Given these positive results, they plan to start follow-up studies at the end of this year.

Van Wijk's research group is already working on the development of a possible treatment for another type of Usher syndrome, namely Usher syndrome type 2C (article in Dutch) (USH2C) using minigenes. The principle of the genetic patch is now also being investigated, albeit with a different approach, as a possible therapy for other disorders, such as for DFNA9 (article in Dutch).

­­­­­­­­­­

Read more about the Usher syndrom (in Dutch)

Questions? Please contact us through ushersyndroom@radboudumc.nl

More information


Pieter Lomans

persvoorlichter

neem contact op

Related news items


Dutch-Nordic Alliance for Precision Cancer Medicine launched

26 November 2021 The Nordic countries (Denmark, Sweden, Norway, and Finland) are together setting up national clinical precision cancer trials modelled on the very successful DRUP trial in the Netherlands. read more

Large AI project receives over €95 million for ten years of public-private research

23 September 2021 The Dutch Research Council (NWO) is to fund two consortia for a period of ten years. Radboudumc participates in the ROBUST consortium, which consists of 17 AI labs, eight of which are dedicated to healthcare. Radboudumc leads five of these eight labs. read more

Nijmegen literally puts Digital Health on the map Flourishing ecosystem gets its own interactive overview

22 July 2021 Digital Health is thriving in the Nijmegen region, where it contributes to better care and health and also creates jobs. To bring developers and end users even closer together, The Economic Board and the Radboudumc are introducing the Interactive Digital Health map. read more

Next Generation cytogenetics is on its way Does Optical Genome Mapping turn cytogenetics upside down?

7 July 2021 Dutch-French research shows that Optical Genome Mapping (OGM) detects abnormalities in chromosomes and DNA very quickly, effectively and accurately. read more

First volunteers vaccinated with Radboudumc malaria vaccine

20 May 2021 Today a new vaccine against malaria, largely developed in Nijmegen, is being tested for the first time in volunteers at Radboudumc. read more

Miljoenen voor kennis- en investeringsconsortium op het gebied van AI

14 April 2021 Een kennis- en investeringsconsortium met het Radboudumc heeft acht miljoen euro subsidie gekregen om innovatie op het gebied van Artificial Intelligence (AI) versneld naar de markt te brengen. read more